{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:22:44Z","timestamp":1782512564765,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.coph.2012.06.005","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T10:56:24Z","timestamp":1341572184000},"page":"556-561","source":"Crossref","is-referenced-by-count":19,"title":["Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV)"],"prefix":"10.1016","volume":"12","author":[{"given":"Colleen M","family":"Wegzyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Wyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2012.06.005_bib0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1 Suppl.","key":"10.1016\/j.coph.2012.06.005_bib0010","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"Alter","year":"2006","journal-title":"J. Hepatol"},{"key":"10.1016\/j.coph.2012.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2012.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl. 2(0)","key":"10.1016\/j.coph.2012.06.005_bib0025","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1016\/S0168-8278(12)61433-0","article-title":"1422 Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +\/\u2212 ribavirin, in treatment-naive patients with chronic HCV GT1, 2, OR 3","volume":"56","author":"Sulkowski","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 2(0)","key":"10.1016\/j.coph.2012.06.005_bib0030","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"1399 12-Week interferon-free regimen of ABT-450\/R +ABT-333 +ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 2(0)","key":"10.1016\/j.coph.2012.06.005_bib0035","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","article-title":"1113 Electron: once daily PSI-7977 plus RBV in HCV GT1\/2\/3","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2012.06.005_bib0040","unstructured":"Edurant Prescribing Information. Raritan, NJ: Tibotec, Inc.; 2011."},{"key":"10.1016\/j.coph.2012.06.005_bib0045","doi-asserted-by":"crossref","DOI":"10.3851\/IMP1959","article-title":"Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects [Internet]","author":"Crauwels","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coph.2012.06.005_bib0050_1","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-na\u00efve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials [Internet]","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coph.2012.06.005_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment naive and treatment experienced patients","volume":"43","author":"DeJesus","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coph.2012.06.005_bib0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2012.06.005_bib0065","series-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Effect of atazanavir\/r on the steady state pharmacokinetcs of elvitegravir [abstract n A-1417]","author":"Mathias","year":"2007"},{"key":"10.1016\/j.coph.2012.06.005_bib0070","series-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"A pharmacokinetic interaction between lopinavir\/r and elvitegravir [abstract n A-1418]","author":"Mathias","year":"2007"},{"key":"10.1016\/j.coph.2012.06.005_bib0075","series-title":"8th International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Pharmacokinetic evaluation of drug interactions with ritonavir boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents [abstract no. 69]","author":"Ramanathan","year":"2007"},{"key":"10.1016\/j.coph.2012.06.005_bib0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2012.06.005_bib0085_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"German","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coph.2012.06.005_bib0090","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [Abstract A1-1724]","author":"Lepist","year":"2011"},{"key":"10.1016\/j.coph.2012.06.005_bib0095","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function [Abstract H2-804]","author":"German","year":"2011"},{"key":"10.1016\/j.coph.2012.06.005_bib0100","series-title":"19th Conference of Retroviruses and Opportunistic Infections","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz\/emtricitabine\/tenofovir in treatment na\u00efve HIV-1 infected subjects [Abstract 101]","author":"Sax","year":"2012"},{"key":"10.1016\/j.coph.2012.06.005_bib0105","series-title":"19th Conference of Retroviruses and Opportunistic Infections","author":"DeJesus","year":"2012"},{"key":"10.1016\/j.coph.2012.06.005_bib0110","series-title":"4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention","article-title":"First report of raltegravir (RAL, MK-0518) use after virological rebound on elvitegravir (EVT, GS 9137) [Abstract TUPEB032]","author":"DeJesus","year":"2007"},{"key":"10.1016\/j.coph.2012.06.005_bib0115","unstructured":"Victrelis (boceprevir) Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2011."},{"key":"10.1016\/j.coph.2012.06.005_bib0120_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0125_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0130","unstructured":"Incivek (telaprevir) Package Insert. Cambridge, MA: Vertex Pharmaceuticals Inc; 2011."},{"key":"10.1016\/j.coph.2012.06.005_bib0135_1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0140","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0145_1","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir [Internet]","author":"Kiser","year":"2012","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4 Suppl.","key":"10.1016\/j.coph.2012.06.005_bib0155","first-page":"1429A","article-title":"TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the pillar phase IIB study","volume":"54","author":"Fried","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2012.06.005_bib0160","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"High rates of SVR24 for BMS-790052, an NS5A replication complex inhibitor, in combination with PegIFN-alfa-2a and ribavirin: phase 2a trial in treatment-naive HCV genotype 1 subjects [Abstract H1-376]","author":"Pol","year":"2011"},{"issue":"Suppl. 2(0)","key":"10.1016\/j.coph.2012.06.005_bib0165","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)00243-7","article-title":"1 Atomic: 97% RVR for PSI-7977+PEG\/RBV\u00d712 week regimen in HCV GT1: an end to response-guided therapy?","volume":"56","author":"Kowdlev","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2012.06.005_bib0170_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.06.005_bib0175","series-title":"19th Conference of Retroviruses and Opportunistic Infections","article-title":"Pharmacokinetic interaction between the HCV protease inhibitor Boceprevir and ritonavir-boosted HIV-1 protease inhibitors Atazanavir, Lopinavir, and Darunavir [Abstract 771LB]","author":"Hulskotte","year":"2012"},{"key":"10.1016\/j.coph.2012.06.005_bib0180","series-title":"19th Conference of Retroviruses and Opportunistic Infections","article-title":"Influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [Abstract 772LB]","author":"de Kanter","year":"2012"},{"key":"10.1016\/j.coph.2012.06.005_bib0185","series-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"The pharmacokinetics between telaprevir and raltegravir in healthy volunteers [Abstract A1-1738a]","author":"Van Heeswiijk","year":"2011"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T09:28:14Z","timestamp":1542878894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489212001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1471489212001038"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2012.06.005","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}